|
|
|
A lasting performance shown to play on... an enduring symphony in RA
|
A lasting performance shown to play on... an enduring symphony in RA
ENBREL
#1 biologic dispensed by rheumatologists
Demonstrated sustained EFFICACY with no dose escalation
Long-term SAFETY profile demonstrated
Established EXPERIENCE
Demonstrated sustained EFFICACY with no dose escalation
Long-term SAFETY profile demonstrated
Established EXPERIENCE
•Early RA: Sustained ACR scores over 5 years in open-label extension trial'
•Established RA: 78% of patients (n=213) receiving ENBREL + MTX had no radiographic progression (change from baseline in TSS ~0.5 units) after 2 years
•No increase in serious I nfection rate over 6 years in RA clinical trials (incidence rate of 0.034 at Year 1 [n=1.341] vs. 0.016 at Year 6 [n=425]
•No cases of TB reactivation in clinical trlals
•In RA clinical trials, the rate of lymphoma was 0.09/100 patient-years
•15 years clinical experience worldwide, 7 years in Canadian practice
Enbrel etanercept
Endurance
=================================
ENBREL is indicated for reducing Signs and symptoms, inhibiting structural damage progression and improving physical function of moderately to severely active arthritis in adult patients with rheumatoid arthritis (RA) and psoriatic arthritis PsA), ENBREL can he Initiated in combination with methotrexate in adult patients or used alone in RA and PsA ENBREL is also indicated for reducing signs and symptoms of active ankylosing spondylitis (AS).
|
|
| Rate this file (No vote yet) |
|
|
|
|
|
|
